Prescribing information

 

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis in adults, adolescents and children from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated CRP and/or MRI evidence in adults who have responded inadequately to NSAIDs.

Hear patients supported by You First discuss the impact the programme has had on their life.

 

 

 

Click here for Cosentyx (secukinumab) prescribing information

You First: Jane’s patient experience

Hear You First patient Jane discussing how the You First programme has supported her to manage her plaque psoriasis.

 

 

Click here for Cosentyx (secukinumab) prescribing information

You First: Catherine’s patient experience

You First patient Catherine and You First nurse Sue discuss the support that the dedicated You First nurse can provide to patients with plaque psoriasis.

 

CRP, C-reactive protein; DMARD, disease-modifying anti-rheumatic drug; MRI, magnetic resonance imaging; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drug.

Rate this content: 
No votes yet
UK | October 2021 | 154466
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]